Improvement of asthma control with omalizumab in 2 obese pediatric asthma patients

Annals of Allergy, Asthma and Immunology

Volumn 97, Issue 3, 2006, Pages 288-293

  Kwong, Kenny Y C ^a   Jones, Craig A ^a  

^a LAC USC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FEXOFENADINE; FLUTICASONE PROPIONATE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MOMETASONE FUROATE; MONTELUKAST; OMALIZUMAB; OMEPRAZOLE; PROTON PUMP INHIBITOR; SALMETEROL;

ADOLESCENT; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ARTICLE; BODY WEIGHT; CASE REPORT; DISEASE ACTIVITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; EMERGENCY TREATMENT; GASTROESOPHAGEAL REFLUX; HOSPITALIZATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LUNG FUNCTION; MALE; MAXIMUM PERMISSIBLE DOSE; OBESITY; PRIORITY JOURNAL;

EID: 33749163108     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60791-0     Document Type: Article

References (19)

1. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108(2):E36.
2. Holgate ST, Djukanovic R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy. 2005;35:408-416.
3. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005;115:459-465.
4. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184-190.
5. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics: the effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Eur Respir J. 2001;18:254-261.
6. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005;60:302-308.
7. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy. 2004;59:701-708.
8. Humbert M, Beasley R, Ayers J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4. Treatment): INNOVATE. Allergy. 2005;60:309-316.
9. Djukanovic R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170:583-593. Epub 2004 Jun 1.
10. Chinn S. Asthma and obesity: where are we now? Thorax. 2003;58:1008-1010.
11. Weiss ST, Shore S. Obesity and asthma: directions for research. Am J Respir Crit Care Med. 2004;169:963-968.
12. Brenner JS, Kelly CS, Wenger AD, et al. Asthma and obesity in adolescents: is there an association. J Asthma. 2001;38:509-515.
13. Gilliland FD, Berhane K, Islam T, et al. Obesity and the risk of newly diagnosed asthma in school-age children. Am J Epidemol. 2003;158:406-415.
14. Guerra S, Wright AL, Morgan WJ, Sherrill DL, Holberg CJ, Martinez FD. Persistence of asthma symptoms during adolescence: role of obesity and age at the onset of puberty. Am J Respir Crit Care Med. 2004;170:78-85.
15. Bateman ED, Boushey HA, Bousquet J, et al; GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170:836-844. Epub 2004 Jul 15.
16. Bateman ED, Frith LF, Braunstein GL. Achieving guideline-based asthma control: does the patient benefit? Eur Respir J. 2002;20:588-595.
17. Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med. 2002;165:1377-1383.
18. Szefler SJ, Martin RJ, King TS, et al; Asthma Clinical Research Network of the National Heart Lung, and Blood Institute. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002;109:410-418.
19. Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol. 2000;18:157-162.